Display options
Cite
Ahring KK, Dagnæs-Hansen F, Brüel A, et al. The effect of casein glycomacropeptide versus free synthetic amino acids for early treatment of phenylketonuria in a mice model. PLoS One. 2022;17(1):e0261150doi: 10.1371/journal.pone.0261150.
Ahring, K. K., Dagnæs-Hansen, F., Brüel, A., Christensen, M., Jensen, E., Jensen, T. G., Johannsen, M., Johansen, K. S., Lund, A. M., Madsen, J. G., Brøndum-Nielsen, K., Pedersen, M., Sørensen, L. K., Kjolby, M., & Møller, L. B. (2022). The effect of casein glycomacropeptide versus free synthetic amino acids for early treatment of phenylketonuria in a mice model. PloS one, 17(1), e0261150. https://doi.org/10.1371/journal.pone.0261150
Ahring, Kirsten K, et al. "The effect of casein glycomacropeptide versus free synthetic amino acids for early treatment of phenylketonuria in a mice model." PloS one vol. 17,1 (2022): e0261150. doi: https://doi.org/10.1371/journal.pone.0261150
Ahring KK, Dagnæs-Hansen F, Brüel A, Christensen M, Jensen E, Jensen TG, Johannsen M, Johansen KS, Lund AM, Madsen JG, Brøndum-Nielsen K, Pedersen M, Sørensen LK, Kjolby M, Møller LB. The effect of casein glycomacropeptide versus free synthetic amino acids for early treatment of phenylketonuria in a mice model. PLoS One. 2022 Jan 11;17(1):e0261150. doi: 10.1371/journal.pone.0261150. eCollection 2022. PMID: 35015767.
Copy Download .nbib Format: NLM
Share it on

PLoS One. 2022 Jan 11;17(1):e0261150. doi: 10.1371/journal.pone.0261150. eCollection 2022.

The effect of casein glycomacropeptide versus free synthetic amino acids for early treatment of phenylketonuria in a mice model.

PloS one

Kirsten K Ahring, Frederik Dagnæs-Hansen, Annemarie Brüel, Mette Christensen, Erik Jensen, Thomas G Jensen, Mogens Johannsen, Karen S Johansen, Allan M Lund, Jesper G Madsen, Karen Brøndum-Nielsen, Michael Pedersen, Lambert K Sørensen, Mads Kjolby, Lisbeth B Møller

Affiliations

  1. Departments of Paediatrics and Clinical Genetics, PKU Clinic, Kennedy Center, Copenhagen University Hospital, Rigshospitalet, Denmark.
  2. Department of Biomedicine, Health, Aarhus University, Aarhus, Denmark.
  3. Departments of Paediatrics and Clinical Genetics, Centre for Inherited Metabolic Diseases, Copenhagen University Hospital, Rigshospitalet, Denmark.
  4. Arla Foods Ingredients Group P/S, Viby J, Denmark.
  5. Department of Forensic Medicine, Aarhus University, Skejby, Aarhus, Denmark.
  6. Comparative Medicine Lab, Aarhus University Hospital, Aarhus, Denmark.
  7. Steno Diabetes Center Aarhus, Aarhus University Hospital, Aarhus, Denmark.
  8. Department of Clinical Pharmacology, Aarhus University Hospital, Aarhus, Denmark.
  9. Department of Clinical Genetics, Kennedy Center, Copenhagen University Hospital, Rigshospitalet, Denmark.

PMID: 35015767 DOI: 10.1371/journal.pone.0261150

Abstract

INTRODUCTION: Management of phenylketonuria (PKU) is mainly achieved through dietary control with limited intake of phenylalanine (Phe) from food, supplemented with low protein (LP) food and a mixture of free synthetic (FS) amino acids (AA) (FSAA). Casein glycomacropeptide (CGMP) is a natural peptide released in whey during cheese making by the action of the enzyme chymosin. Because CGMP in its pure form does not contain Phe, it is nutritionally suitable as a supplement in the diet for PKU when enriched with specific AAs. Lacprodan® CGMP-20 (= CGMP) used in this study contained only trace amounts of Phe due to minor presence of other proteins/peptides.

OBJECTIVE: The aims were to address the following questions in a classical PKU mouse model: Study 1, off diet: Can pure CGMP or CGMP supplemented with Large Neutral Amino Acids (LNAA) as a supplement to normal diet significantly lower the content of Phe in the brain compared to a control group on normal diet, and does supplementation of selected LNAA results in significant lower brain Phe level?. Study 2, on diet: Does a combination of CGMP, essential (non-Phe) EAAs and LP diet, provide similar plasma and brain Phe levels, growth and behavioral skills as a formula which alone consist of FSAA, with a similar composition?.

MATERIAL AND METHODS: 45 female mice homozygous for the Pahenu2 mutation were treated for 12 weeks in five different groups; G1(N-CGMP), fed on Normal (N) casein diet (75%) in combination with CGMP (25%); G2 (N-CGMP-LNAA), fed on Normal (N) casein diet (75%) in combination with CGMP (19,7%) and selected LNAA (5,3% Leu, Tyr and Trp); G3 (N), fed on normal casein diet (100%); G4 (CGMP-EAA-LP), fed on CGMP (70,4%) in combination with essential AA (19,6%) and LP diet; G5 (FSAA-LP), fed on FSAA (100%) and LP diet. The following parameters were measured during the treatment period: Plasma AA profiles including Phe and Tyr, growth, food and water intake and number of teeth cut. At the end of the treatment period, a body scan (fat and lean body mass) and a behavioral test (Barnes Maze) were performed. Finally, the brains were examined for content of Phe, Tyr, Trp, dopamine (DA), 3,4-dihydroxyphenylacetic acid (DOPAC), serotonin (5-HT) and 5-hydroxyindole-acetic acid (5-HIAA), and the bone density and bone mineral content were determined by dual-energy x-ray absorptiometry.

RESULTS: Study 1: Mice off diet supplemented with CGMP (G1 (N-CGMP)) or supplemented with CGMP in combination with LNAA (G2 (N-CGMP-LNAA)) had significantly lower Phe in plasma and in the brain compared to mice fed only casein (G3 (N)). Extra LNAA (Tyr, Trp and Leu) to CGMP did not have any significant impact on Phe levels in the plasma and brain, but an increase in serotonin was measured in the brain of G2 mice compared to G1. Study 2: PKU mice fed with mixture of CGMP and EAA as supplement to LP diet (G4 (CGMP-EAA-LP)) demonstrated lower plasma-Phe levels but similar brain- Phe levels and growth as mice fed on an almost identical combination of FSAA (G5 (FSAA-LP)).

CONCLUSION: CGMP can be a relevant supplement for the treatment of PKU.

Conflict of interest statement

Erik Jensen was the industrial supervisor for the above described PhD project, and his mandatory obligation was to contribute with inputs to study design, formulation of test diets and study manuscrip

Publication Types